ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Rapid Micro Biosystems Inc

Rapid Micro Biosystems Inc (RPID)

0.869
0.00
(0.00%)
Closed September 20 4:00PM
0.00
0.00
(0.00%)

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.869
Bid
0.8403
Ask
0.91
Volume
-
0.00 Day's Range 0.00
0.58 52 Week Range 1.18
Market Cap
Previous Close
0.869
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
61,220
Shares Outstanding
42,914,151
Dividend Yield
-
PE Ratio
-0.71
Earnings Per Share (EPS)
-1.22
Revenue
22.52M
Net Profit
-52.47M

About Rapid Micro Biosystems Inc

Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flags... Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services. Show more

Sector
Lab Analytical Instruments
Industry
Lab Analytical Instruments
Headquarters
Delaware, Ohio, USA
Founded
-
Rapid Micro Biosystems Inc is listed in the Lab Analytical Instruments sector of the NASDAQ with ticker RPID. The last closing price for Rapid Micro Biosystems was $0.87. Over the last year, Rapid Micro Biosystems shares have traded in a share price range of $ 0.58 to $ 1.18.

Rapid Micro Biosystems currently has 42,914,151 shares outstanding. The market capitalization of Rapid Micro Biosystems is $37.29 million. Rapid Micro Biosystems has a price to earnings ratio (PE ratio) of -0.71.

RPID Latest News

Rapid Micro Biosystems to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

LEXINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical...

Rapid Micro Biosystems Reports Second Quarter 2024 Financial Results

Record second quarter 2024 revenue of $6.6 million, representing growth of 32% compared to the second quarter of 2023150th Growth Direct® system placed with an existing top 15 global pharma...

Rapid Micro Biosystems to Announce Second Quarter 2024 Financial Results on August 2, 2024

LOWELL, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0091.046511627910.860.90.831041430.84344002CS
40.0192.235294117650.850.90.8009623690.84179823CS
120.19929.70149253730.670.950.58612200.80374648CS
26-0.1008-10.39389564860.96981.020.58466870.83001276CS
52-0.271-23.77192982461.141.180.58846320.92375844CS
156-19.131-95.6552022.710.581096464.55158236CS
260-21.631-96.137777777822.527.040.581186186.68379559CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.158
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 64.25
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.83
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 9.75
(0.00%)
0
AACGATA Creativity Global
$ 0.53
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.158
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 64.25
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.83
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 9.75
(0.00%)
0
AACGATA Creativity Global
$ 0.53
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.158
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 64.25
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.83
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 9.75
(0.00%)
0
AACGATA Creativity Global
$ 0.53
(0.00%)
0

RPID Discussion

View Posts
tw0122 tw0122 9 months ago
Samsung Biologics selects Rapid Micro Biosystems’ Growth Direct® platform to automate critical microbiology quality control testing

Source: GlobeNewswire Inc.

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that Samsung Biologics (KRX: 207940.KS) has selected the Growth Direct® platform to automate its microbial quality control processes to deliver increased efficiency, more robust data integrity and scalable quality control operations.
“Samsung Biologics is a leading global contract development and manufacturing organization (CDMO) and has demonstrated an unwavering commitment to automation and quality management in biopharmaceutical manufacturing,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems. “The Growth Direct® improves operational efficiency and data integrity in the quality control microbiology lab, and we are proud to partner with Samsung Biologics.”

Global pharmaceutical manufacturers rely on the Growth Direct platform to meet both today’s microbiological quality control standards and tomorrow’s challenges. It is the only fully automated, non-destructive growth-based platform for microbiology quality control testing that offers faster time to results, improved data integrity, and enhanced accuracy, with greater sample capacity.

To learn more about the Company and the Growth Direct® platform please visit: Rapid Micro Biosystems.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on Twitter at @rapidmicrobio or on LinkedIn.

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are cGMP compliant with bioreactors ranging from small to large scales to serve varying client needs. To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demand, Samsung Biologics recently completed Bio Campus I with Plant 4 offering a combined 604KL total capacity, and launched Bio Campus II with the construction of Plant 5, which will be operational in April 2025 adding 184KL biomanufacturing capacity. Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe. We continue to upgrade our capabilities to accommodate our clients by investing in technologies such as an antibody-drug conjugate (ADC) facility, a dedicated mRNA manufacturing facility, and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise.
👍️0

Your Recent History

Delayed Upgrade Clock